| A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis DF Martin, J Sierra-Madero, S Walmsley, RA Wolitz, K Macey, P Georgiou, ... New England Journal of Medicine 346 (15), 1119-1126, 2002 | 487 | 2002 |
| Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial G Reyes-Terán, JG Sierra-Madero, VM del Cerro, H Arroyo-Figueroa, ... Aids 10 (13), 1501-1507, 1996 | 249 | 1996 |
| Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in … P Cahn, J Andrade-Villanueva, JR Arribas, JM Gatell, JR Lama, M Norton, ... The Lancet Infectious Diseases 14 (7), 572-580, 2014 | 205 | 2014 |
| The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients: a 12-year study in a referral center in Mexico V Ramírez-Amador, L Esquivel-Pedraza, J Sierra-Madero, ... Medicine 82 (1), 39-50, 2003 | 205 | 2003 |
| Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in Mexico City: a prospective cohort study E Ortiz-Brizuela, M Villanueva-Reza, MF González-Lara, ... Revista de investigacion clinica 72 (3), 165-177, 2020 | 160 | 2020 |
| Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated … C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ... The Lancet HIV 4 (12), e536-e546, 2017 | 136 | 2017 |
| Fulminant amebic colitis: analysis of 55 cases T Takahashi, A Gamboa-Dominguez, TJM Gomez-Mendez, JM Remes, ... Diseases of the colon & rectum 40 (11), 1362-1367, 1997 | 106 | 1997 |
| Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type 1. Z Toossi, JG Sierra-Madero, RA Blinkhorn, MA Mettler, EA Rich The Journal of experimental medicine 177 (5), 1511-1516, 1993 | 105 | 1993 |
| Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey S Ávila-Ríos, C García-Morales, M Matías-Florentino, KA Romero-Mora, ... The lancet HIV 3 (12), e579-e591, 2016 | 103 | 2016 |
| Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters B Crabtree-Ramirez, Y Caro-Vega, BE Shepherd, F Wehbe, C Cesar, ... PloS one 6 (5), e20272, 2011 | 103 | 2011 |
| Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study M García-Grimshaw, LE Hernández-Vanegas, I Núñez, ... Clinical Immunology 229, 108786, 2021 | 98 | 2021 |
| Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study J Sierra-Madero, G Di Perri, R Wood, M Saag, I Frank, C Craig, ... HIV clinical trials 11 (3), 125-132, 2010 | 89 | 2010 |
| Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis MA Boyd, CL Moore, JM Molina, R Wood, JS Madero, M Wolff, ... The lancet HIV 2 (2), e42-e51, 2015 | 85 | 2015 |
| The HIV care continuum in Latin America: challenges and opportunities A Piñeirúa, J Sierra-Madero, P Cahn, RNG Palmero, EM Buitrago, ... The Lancet Infectious Diseases 15 (7), 833-839, 2015 | 84 | 2015 |
| Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+< 200 cell/mm3 in Mexico J Sierra-Madero, A Villasis-Keever, P Méndez, JL Mosqueda-Gómez, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 53 (5), 582-588, 2010 | 84 | 2010 |
| Escala de Ansiedad y Depresión Hospitalaria (HADS): Validación en pacientes mexicanos con infección por VIH MJN Orozco, BP Terán, VB Casarrubias, RR García, JGS Madero Psicología Iberoamericana 21 (2), 29-37, 2013 | 83 | 2013 |
| Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone CC Knapp, J Sierra-Madero, JA Washington Antimicrobial agents and chemotherapy 32 (12), 1896-1898, 1988 | 80 | 1988 |
| A cross-sectional study of prisoners in Mexico City comparing prevalence of transmissible infections and chronic diseases with that in the general population S Bautista-Arredondo, A González, E Servan-Mori, F Beynon, ... PloS one 10 (7), e0131718, 2015 | 79 | 2015 |
| Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America C Cesar, BE Shepherd, AJ Krolewiecki, VI Fink, M Schechter, SH Tuboi, ... PLoS One 5 (6), e10490, 2010 | 79 | 2010 |
| Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City V Ramirez-Amador, S Ponce-de-León, G Anaya-Saavedra, BC Ramírez, ... Clinical infectious diseases 45 (7), 925-932, 2007 | 75 | 2007 |
